Ulipristal is a safe and effective option for women with uterine fibroids, according to two new studies published in the New England Journal of Medicine. In both studies, the oral selective progesterone receptor modulator was well-tolerated, rapidly reduced excessive bleeding, and decreased the size of uterine fibroids.
Your patient just received devastating news: she has cancer. As treatment options and anxieties swirl, more and more women are now faced with another issue: how will the cancer and its treatment impact their fertility?
Orthodox Jewish women may follow an ancient tradition that requires sexual abstention during her menses and for the seven days that follow. Once the woman has completed the period of sexual abstention she immerses in a ritual bath to purify her soul and then is encouraged to have intercourse with her husband but when your patient experiences infertility, how do you treat the infertility while maintaining respect for her religious traditions?
Two new studies published in the New England Journal of Medicine point to the importance of using bevacizumab in the treatment of ovarian cancer. Bevacizumab, a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor, has shown single-agent activity in women with recurrent tumors.
Endometriosis affects as many as 6% of the general population. While some women with endometriosis remain asymptomatic, many women experience dysmenorrhea, dyspareunia, non-cyclical pelvic pain, and subfertility. Now, new research indicates that patients with endometriosis are also more likely to develop inflammatory bowel disease.
As infertility rates have increased, now affecting as many as 12% of the reproductive age population, so has the use of assisted conception. For instance, in vitro fertilization was employed in about 1% of all live births in the United States.
Lead researcher Dr Janet McLaren discusses the results of a new study exploring new concerns that rheumatoid arthritis, lupus, and inflammatory bowel disease may lead to premature ovarian failure and early menopause.
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 19th Annual Meeting of ESHRE - Madrid, Spain
OBGYN.net Conference Coveragefrom the 18th Annual Meeting of ESHRE - Vienna, Austria
OBGYN.net Conference Coveragefrom the 18th Annual Meeting of ESHRE - Vienna, Austria
OBGYN.net Conference Coveragefrom the 18th Annual Meeting of ESHRE - Vienna, Austria
OBGYN.net Conference Coveragefrom the 18th Annual Meeting of ESHRE - Vienna, Austria
OBGYN.net Conference Coveragefrom the 18th Annual Meeting of ESHRE - Vienna, Austria
OBGYN.net Conference CoverageFrom the ESHRE 2001 Conference - Lausanne, Switzerland
OBGYN.net Conference CoverageFrom the ESHRE 2001 Conference - Lausanne, Switzerland
OBGYN.net Conference CoverageFrom the ESHRE 2001 Conference - Lausanne, Switzerland
